The BRD8 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human cervical adenocarcinoma HeLa cell line, designed to disrupt the BRD8 gene. This loss-of-function model enables systematic investigation of BRD8-dependent processes in an epithelial cancer background, without claims of monoclonality or complete gene inactivation. The polyclonal format offers a representative genetic perturbation landscape suitable for population-based functional genomics assays.
The parental HeLa cell line is an aneuploid, HPV-18 positive, immortalized cervical carcinoma line that has been extensively characterized for cancer research and gene perturbation studies. Its robust proliferation, well-documented signal transduction pathways, and transformability make it a versatile host for CRISPR-mediated gene disruption, allowing researchers to examine the consequences of BRD8 loss in a pathologically relevant cellular setting.
BRD8 encodes a bromodomain-containing protein that functions as a core subunit of the NuA4/Tip60 histone acetyltransferase complex. Within this complex, BRD8 interacts with EP400, TRRAP, RUVBL1, and RUVBL2 to catalyze acetylation of histone H4 and H2A, thereby relaxing chromatin and facilitating transcriptional activation. BRD8 acts as a coactivator for nuclear receptors, including ESR1 and AR, and is regulated by upstream signals such as DNA damage and nuclear receptor ligands. Its activity promotes histone H4 acetylation at target gene promoters, influencing downstream expression of genes involved in cell cycle control and DNA repair.
In the HeLa cervical adenocarcinoma context, disruption of BRD8 is expected to compromise the integrity and acetylation activity of the NuA4/Tip60 complex, leading to reduced histone H4 acetylation at loci regulated by nuclear receptors and other transcription factors. This perturbation may reveal BRD8-dependent transcriptional networks governing proliferation, survival, and genomic stability??processes frequently dysregulated in cervical and other cancers. The model thus provides a platform to dissect BRD8??s contribution to oncogenic signaling and chromatin remodeling within a naturally transformed epithelial environment.
Researchers can deploy these polyclonal knockout cells in a variety of experimental workflows, including chromatin immunoprecipitation to map changes in histone H4 acetylation, quantitative RT-PCR and RNA-seq for transcriptomic profiling, and luciferase reporter assays to measure ESR1/AR transcriptional activity. Additional applications encompass co-immunoprecipitation to assess NuA4/Tip60 complex assembly, immunofluorescence for acetyl-histone H4, cell proliferation studies, and DNA damage response assays using ??H2AX foci quantification. The model supports functional genomics and drug target validation efforts in cancer biology and nuclear receptor signaling. For further information, please contact Ascent Research.
